Please enter a valid ZIP code

NovoSeven® RT (Coagulation Factor VIIa [Recombinant]) is the only bypassing agent FDA approved for acquired hemophilia

What is acquired hemophilia?

Acquired hemophilia Acquired hemophilia
A form of hemophilia in which the body starts producing antibodies that fight its own blood-clotting proteins.
is a rare and dangerous blood disorder. Each year, it occurs in only 1 to 1.5 per 1 million people. Acquired hemophilia is associated with a wide range of conditions. With acquired hemophilia:

  • Spontaneous Spontaneous
    Something that happens on its own, for what seems like no reason. For example, spontaneous bleeding does not appear to have a specific cause.
    , uncontrolled bleeding Bleeding
    In hemophilia, a collection of blood in an area, such as a muscle or joint.
    can occur
  • Men and women with no personal or family history of the disease are affected
Symptoms and diagnosis of acquired hemophilia

Acquired hemophilia is hard to detect. The most common symptoms are:

  • Bleeding into the skin
  • Bleeding into soft tissues
  • Internal bleeding Internal bleeding
    Bleeding inside the body, in tissues or organs.
  • Excessive bleeding following surgery
  • Excessive bleeding after childbirth

Acquired hemophilia is diagnosed with laboratory tests that measure clotting time Clotting time
The time required for blood to clot.
of blood and factor VIII (8) Factor VIII (8)
One of the 13 clotting-factor proteins that helps form blood clots.

Indications and Usage

NovoSeven® RT (Coagulation Factor VIIa [Recombinant]) is used for:

Important Safety Information


  • Serious blood clots that form in veins and arteries with the use of NovoSeven® RT have been reported.
  • Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function.
  • Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT.

Warnings and Precautions

Side Effects

Use with Other Drugs

Please click here for NovoSeven® RT Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit,
or call 1-800-FDA-1088.

NovoSeven® RT is a prescription medicine. Novo Nordisk provides patient assistance for those who qualify. Please call 1-877-NOVO-777 (1-877-668-6777) to learn more about Novo Nordisk assistance programs.